Home LiteratureArticle Details
PMID: 16920826 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.

Journal of virology ·Vol. 80 ·No. 21 ·2006-11-00 ·Pages 10522-33

Dang Y, Wang X, Esselman WJ, Zheng YH

Abstract

A tandem arrayed gene cluster encoding seven cytidine deaminase genes is present on human chromosome 22. These are APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3DE, APOBEC3F, APOBEC3G, and APOBEC3H. Three of them, APOBEC3G, APOBEC3F, and APOBEC3B, block replication of human immunodeficiency virus type 1 (HIV-1) and many other retroviruses. In addition, APOBEC3A and APOBEC3C block intracellular retrotransposons and simian immunodeficiency virus (SIV), respectively. In opposition to APOBEC genes, HIV-1 and SIV contain a virion infectivity factor (Vif) that targets APOBEC3F and APOBEC3G for polyubiquitylation and proteasomal degradation. Herein, we studied the antiretroviral activities of the human APOBEC3DE and APOBEC3H. We found that only APOBEC3DE had antiretroviral activity for HIV-1 or SIV and that Vif suppressed this antiviral activity. APOBEC3DE was encapsidated and capable of deaminating cytosines to uracils on viral minus-strand DNA, resulting in disruption of the viral life cycle. Other than GG-to-AG and AG-to-AA mutations, it had a novel target site specificity, resulting in introduction of GC-to-AC mutations on viral plus-strand DNA. Such mutations have been detected previously in HIV-1 clinical isolates. In addition, APOBEC3DE was expressed much more extensively than APOBEC3F in various human tissues and it formed heteromultimers with APOBEC3F or APOBEC3G in the cell. From these studies, we concluded that APOBEC3DE is a new contributor to the intracellular defense network, resulting in suppression of retroviral invasion.

MeSH Terms
APOBEC Deaminases Amino Acid Sequence Animals Anti-HIV Agents/metabolism Anti-Retroviral Agents/metabolism Cell Line Cytidine Deaminase Cytosine Deaminase/genetics,physiology DNA, Complementary/genetics DNA, Viral/genetics Gene Products, vif/physiology HIV-1/genetics,physiology Humans Leukemia Virus, Murine/physiology Models, Biological Molecular Sequence Data Multigene Family Point Mutation Proteasome Endopeptidase Complex/metabolism RNA, Messenger/genetics,metabolism Retroviridae/pathogenicity Sequence Homology, Amino Acid Simian Immunodeficiency Virus/physiology Virus Replication vif Gene Products, Human Immunodeficiency Virus
Chemicals
Anti-HIV Agents Anti-Retroviral Agents DNA, Complementary DNA, Viral Gene Products, vif RNA, Messenger vif Gene Products, Human Immunodeficiency Virus Proteasome Endopeptidase Complex Cytosine Deaminase APOBEC Deaminases APOBEC3 protein, human Cytidine Deaminase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Dang Ying
Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan 48824-4320, USA.
Wang Xiaojun
Esselman Walter J
Zheng Yong-Hui
References (72)
72 references, click to expand
  1. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
    Genes Dev. 2004 Dec 1;18(23):2861-6 PMID: 15574592
  2. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
    Genomics. 2002 Mar;79(3):285-96 PMID: 11863358
  3. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.
    Nucleic Acids Res. 2006;34(1):89-95 PMID: 16407327
  4. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.
    J Virol. 2001 Aug;75(16):7252-65 PMID: 11461998
  5. Molecular cloning of an apolipoprotein B messenger RNA editing protein.
    Science. 1993 Jun 18;260(5115):1816-9 PMID: 8511591
  6. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.
    Virology. 2006 May 25;349(1):31-40 PMID: 16460778
  7. APOBEC3G targets specific virus species.
    J Virol. 2004 Aug;78(15):8238-44 PMID: 15254195
  8. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis.
    Cell Cycle. 2005 Sep;4(9):1281-5 PMID: 16082223
  9. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Science. 2003 Nov 7;302(5647):1056-60 PMID: 14564014
  10. Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA.
    J Mol Biol. 2005 Nov 18;354(1):55-72 PMID: 16236319
  11. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7 PMID: 15054139
  12. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
    J Biol Chem. 2004 Dec 17;279(51):53379-86 PMID: 15466872
  13. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles.
    Biochem Biophys Res Commun. 2004 Aug 27;321(3):566-73 PMID: 15358144
  14. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.
    Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11444-9 PMID: 16076960
  15. HIV accessory proteins: multifunctional components of a complex system.
    Adv Pharmacol. 2000;48:75-120 PMID: 10987089
  16. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Curr Biol. 2005 Jan 26;15(2):166-70 PMID: 15668174
  17. APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
    J Virol. 2004 Nov;78(21):12058-61 PMID: 15479846
  18. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.
    J Virol. 1992 Nov;66(11):6489-95 PMID: 1357189
  19. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.
    J Virol. 1996 Jan;70(1):494-507 PMID: 8523563
  20. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  21. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.
    J Virol. 2006 Feb;80(3):1067-76 PMID: 16414984
  22. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Cell. 2003 Jul 11;114(1):21-31 PMID: 12859895
  23. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells.
    J Biol Chem. 1999 Jun 25;274(26):18470-6 PMID: 10373455
  24. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Curr Biol. 2004 Aug 10;14(15):1385-91 PMID: 15296757
  25. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
    J Virol. 2004 Jun;78(11):6073-6 PMID: 15141007
  26. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription.
    J Virol. 2000 Oct;74(19):8938-45 PMID: 10982337
  27. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
    J Biol Chem. 2004 Aug 13;279(33):34083-6 PMID: 15215254
  28. A quantitative assay for HIV DNA integration in vivo.
    Nat Med. 2001 May;7(5):631-4 PMID: 11329067
  29. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    J Virol. 2004 Nov;78(21):11841-52 PMID: 15479826
  30. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
    Nat Struct Mol Biol. 2004 May;11(5):435-42 PMID: 15098018
  31. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8780-5 PMID: 16728505
  32. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.
    Virology. 2005 Sep 1;339(2):281-8 PMID: 15993456
  33. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification.
    PLoS Pathog. 2005 Sep;1(1):e6 PMID: 16201018
  34. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    AIDS Res Hum Retroviruses. 2005 Jul;21(7):611-9 PMID: 16060832
  35. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
    Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3927-32 PMID: 14978281
  36. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.
    Genes Dev. 2004 Dec 1;18(23):2867-72 PMID: 15574593
  37. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
    J Biol Chem. 2005 Mar 25;280(12):10920-4 PMID: 15647250
  38. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    J Biol Chem. 2004 Aug 20;279(34):35822-8 PMID: 15210704
  39. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Mol Cell. 2003 Sep;12(3):591-601 PMID: 14527406
  40. DNA deamination mediates innate immunity to retroviral infection.
    Cell. 2003 Jun 13;113(6):803-9 PMID: 12809610
  41. The interaction between HIV-1 Gag and APOBEC3G.
    J Biol Chem. 2004 Aug 6;279(32):33177-84 PMID: 15159405
  42. APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle.
    J Biol Chem. 2006 Mar 31;281(13):8309-12 PMID: 16407183
  43. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases.
    Mol Biol Evol. 2005 Feb;22(2):367-77 PMID: 15496550
  44. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  45. Mice deficient in APOBEC2 and APOBEC3.
    Mol Cell Biol. 2005 Aug;25(16):7270-7 PMID: 16055735
  46. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity.
    J Biol Chem. 1995 Jun 16;270(24):14768-75 PMID: 7782343
  47. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
    J Virol. 2005 May;79(9):5870-4 PMID: 15827203
  48. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    J Virol. 2005 Aug;79(15):9579-87 PMID: 16014920
  49. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    J Virol. 2006 Mar;80(6):3112-5 PMID: 16501124
  50. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.
    J Virol. 2006 Apr;80(8):3853-62 PMID: 16571802
  51. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    Curr Biol. 2006 Mar 7;16(5):480-5 PMID: 16527742
  52. Hypermutation of HIV-1 DNA in the absence of the Vif protein.
    Science. 2003 May 16;300(5622):1112 PMID: 12750511
  53. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
    Virology. 2004 Oct 25;328(2):163-8 PMID: 15464836
  54. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.
    J Virol. 2000 Sep;74(18):8252-61 PMID: 10954522
  55. Complementary function of the two catalytic domains of APOBEC3G.
    Virology. 2005 Mar 15;333(2):374-86 PMID: 15721369
  56. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
    Nucleic Acids Res. 2005;33(6):1913-23 PMID: 15809227
  57. Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity, and noncatalytic auxiliary factor(s) of the editing complex are widely distributed.
    J Biol Chem. 1994 Aug 26;269(34):21725-34 PMID: 8063816
  58. Human APOBEC3G incorporation into murine leukemia virus particles.
    Virology. 2005 Jun 20;337(1):175-82 PMID: 15914230
  59. Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.
    J Virol. 1981 Apr;38(1):239-48 PMID: 6165830
  60. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Nat Med. 2003 Nov;9(11):1398-403 PMID: 14528301
  61. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.
    J Virol. 1993 Aug;67(8):4945-55 PMID: 8331734
  62. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
    Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3770-4 PMID: 14999100
  63. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.
    EMBO J. 2004 Jun 16;23(12):2451-8 PMID: 15152192
  64. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.
    J Virol. 2005 Jul;79(13):8201-7 PMID: 15956565
  65. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.
    Trends Genet. 2003 Apr;19(4):207-16 PMID: 12683974
  66. Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
    Curr Biol. 2004 Aug 10;14(15):1392-6 PMID: 15296758
  67. The HIV 'A' (sor) gene product is essential for virus infectivity.
    Nature. 1987 Aug 20-26;328(6132):728-30 PMID: 2441266
  68. Protecting APOBEC3G: a potential new target for HIV drug discovery.
    Curr Opin Investig Drugs. 2005 Feb;6(2):141-7 PMID: 15751736
  69. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  70. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
    J Biol Chem. 2004 Apr 9;279(15):14481-3 PMID: 14966139
  71. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Nat Med. 2003 Nov;9(11):1404-7 PMID: 14528300
  72. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
    J Biol Chem. 2006 Jun 23;281(25):16837-41 PMID: 16648136
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2006-11-00
Epub
2006-00-18
Pages
10522-33
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1641744
Subset
IM
Grants
NIAID NIH HHS · R01 AI063944 · United States
NIAID NIH HHS · R56 AI063944 · United States
NIAID NIH HHS · AI063944 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com